;PMID: 12162759
;source_file_1865.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..121] = [t:45..121]
;2)section:[e:125..155] = [t:125..155]
;3)section:[e:159..307] = [t:159..307]
;4)sentence:[e:311..406] = [t:311..406]
;5)sentence:[e:407..518] = [t:407..518]
;6)sentence:[e:519..662] = [t:519..662]
;7)sentence:[e:663..833] = [t:663..833]
;8)sentence:[e:834..1037] = [t:834..1037]
;9)sentence:[e:1038..1160] = [t:1038..1160]
;10)sentence:[e:1162..1291] = [t:1162..1291]
;11)sentence:[e:1292..1344] = [t:1292..1344]
;12)sentence:[e:1345..1459] = [t:1345..1459]
;13)sentence:[e:1460..1569] = [t:1460..1569]
;14)sentence:[e:1570..1678] = [t:1570..1678]
;15)sentence:[e:1679..1763] = [t:1679..1763]
;16)sentence:[e:1765..1896] = [t:1765..1896]
;17)sentence:[e:1897..2007] = [t:1897..2007]
;18)sentence:[e:2008..2130] = [t:2008..2130]
;19)sentence:[e:2131..2222] = [t:2131..2222]
;20)sentence:[e:2224..2273] = [t:2224..2273]
;21)sentence:[e:2274..2356] = [t:2274..2356]
;22)sentence:[e:2357..2492] = [t:2357..2492]
;23)sentence:[e:2493..2593] = [t:2493..2593]
;24)sentence:[e:2594..2733] = [t:2594..2733]
;25)sentence:[e:2734..2850] = [t:2734..2850]
;26)sentence:[e:2851..2994] = [t:2851..2994]
;27)section:[e:2998..3016] = [t:2998..3016]
;28)section:[e:3022..3028] = [t:3022..3028]
;29)section:[e:3034..3050] = [t:3034..3050]
;30)section:[e:3054..3099] = [t:3054..3099]

;section 0 Span:0..39
;Clin Pharmacokinet. 2002;41(10):719-39.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..18] Pharmacokinet) (.:[18..19] .)
        ('':[20..24] 2002) (CC:[24..28] ;41-LRB-) (CD:[28..30] 10)
        (NN:[30..31] -RRB-) (::[31..32] :) (CD:[32..35] 719) (::[35..36] -)
        (CD:[36..38] 39) (.:[38..39] .)))

;sentence 1 Span:45..121
;Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
;[95..109]:substance:"cholinesterase"
;[110..120]:substance:"inhibitors"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP-1 (JJ:[45..53] Clinical))
        (NNS:[54..70] pharmacokinetics))
      (CC:[71..74] and)
      (NP
        (ADJP-1 (-NONE-:[74..74] *P*))
        (NNS:[75..91] pharmacodynamics)))
    (PP (IN:[92..94] of)
      (NP (NN:[95..109] cholinesterase) (NNS:[110..120] inhibitors)))
    (.:[120..121] .)))

;section 2 Span:125..155
;Jann MW, Shirley KL, Small GW.
(SEC
  (FRAG (NNP:[125..129] Jann) (NNP:[130..132] MW) (,:[132..133] ,)
        (NNP:[134..141] Shirley) (NNP:[142..144] KL) (,:[144..145] ,)
        (NNP:[146..151] Small) (NNP:[152..154] GW) (.:[154..155] .)))

;section 3 Span:159..307
;Department of Clinical and Administrative Sciences, Southern School of
;Pharmacy,  Mercer University, Atlanta, Georgia 30341, USA.
;jann_mw@mercer.edu
(SEC
  (FRAG (NNP:[159..169] Department) (IN:[170..172] of) (NNP:[173..181] Clinical)
        (CC:[182..185] and) (NNP:[186..200] Administrative)
        (NNP:[201..209] Sciences) (,:[209..210] ,) (NNP:[211..219] Southern)
        (NNP:[220..226] School) (IN:[227..229] of) (NNP:[230..238] Pharmacy)
        (,:[238..239] ,) (NNP:[241..247] Mercer) (NNP:[248..258] University)
        (,:[258..259] ,) (NNP:[260..267] Atlanta) (,:[267..268] ,)
        (NNP:[269..276] Georgia) (CD:[277..282] 30341) (,:[282..283] ,)
        (NNP:[284..287] USA) (.:[287..288] .) (IN:[289..303] jann_mw@mercer)
        (NN:[303..307] .edu)))

;sentence 4 Span:311..406
;Cholinesterase inhibitors are the 'first-line' agents in the treatment of 
;Alzheimer's disease.
;[311..325]:substance:"Cholinesterase"
;[326..336]:substance:"inhibitors"
;[358..364]:substance:"agents"
(SENT
  (S
    (NP-SBJ (NN:[311..325] Cholinesterase) (NNS:[326..336] inhibitors))
    (VP (VBP:[337..340] are)
      (NP-PRD (DT:[341..344] the)
        (NML (``:[345..346] ') (JJ:[346..351] first) (HYPH:[351..352] -)
             (NN:[352..356] line) ('':[356..357] '))
        (NNS:[358..364] agents))
      (PP (IN:[365..367] in)
        (NP
          (NP (DT:[368..371] the) (NN:[372..381] treatment))
          (PP (IN:[382..384] of)
            (NP
              (NP (NNP:[386..395] Alzheimer) (POS:[395..397] 's))
              (NN:[398..405] disease))))))
    (.:[405..406] .)))

;sentence 5 Span:407..518
;This article presents the latest information on their  pharmacokinetic
;properties and pharmacodynamic activity.
(SENT
  (S
    (NP-SBJ (DT:[407..411] This) (NN:[412..419] article))
    (VP (VBZ:[420..428] presents)
      (NP
        (NP (DT:[429..432] the) (JJS:[433..439] latest)
            (NN:[440..451] information))
        (PP (IN:[452..454] on)
          (NP (PRP$:[455..460] their)
            (NML
              (NML (JJ:[462..477] pharmacokinetic) (NNS:[478..488] properties))
              (CC:[489..492] and)
              (NML (JJ:[493..508] pharmacodynamic) (NN:[509..517] activity)))))))
    (.:[517..518] .)))

;sentence 6 Span:519..662
;Tacrine was the first  cholinesterase inhibitor approved by regulatory
;agencies, followed by donepezil,  rivastigmine and recently galantamine.
;[519..526]:substance:"Tacrine"
;[542..556]:substance:"cholinesterase"
;[557..566]:substance:"inhibitor"
;[612..621]:substance:"donepezil"
;[624..636]:substance:"rivastigmine"
;[650..661]:substance:"galantamine"
(SENT
  (S
    (NP-SBJ (NN:[519..526] Tacrine))
    (VP (VBD:[527..530] was)
      (NP-PRD
        (NP (DT:[531..534] the) (JJ:[535..540] first)
            (NN:[542..556] cholinesterase) (NN:[557..566] inhibitor))
        (VP (VBN:[567..575] approved)
          (NP (-NONE-:[575..575] *))
          (PP (IN:[576..578] by)
            (NP-LGS (JJ:[579..589] regulatory) (NNS:[590..598] agencies)))))
      (,:[598..599] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[599..599] *))
        (VP
          (VP (VBN:[600..608] followed)
            (PP (IN:[609..611] by)
              (NP=2 (NN:[612..621] donepezil))))
          (,:[621..622] ,)
          (VP
            (NP=2 (NN:[624..636] rivastigmine)))
          (CC:[637..640] and)
          (VP
            (ADVP-TMP (RB:[641..649] recently))
            (NP=2 (NN:[650..661] galantamine))))))
    (.:[661..662] .)))

;sentence 7 Span:663..833
;With the exception of low doses of  tacrine, the cholinesterase inhibitors
;exhibit a linear relationship between  dose and area under the plasma
;concentration-time curve.
;[699..706]:substance:"tacrine"
;[712..726]:substance:"cholinesterase"
;[727..737]:substance:"inhibitors"
(SENT
  (S
    (PP (IN:[663..667] With)
      (NP
        (NP (DT:[668..671] the) (NN:[672..681] exception))
        (PP (IN:[682..684] of)
          (NP
            (NP (JJ:[685..688] low) (NNS:[689..694] doses))
            (PP (IN:[695..697] of)
              (NP (NN:[699..706] tacrine)))))))
    (,:[706..707] ,)
    (NP-SBJ (DT:[708..711] the) (NN:[712..726] cholinesterase)
            (NNS:[727..737] inhibitors))
    (VP (VBP:[738..745] exhibit)
      (NP
        (NP (DT:[746..747] a) (JJ:[748..754] linear)
            (NN:[755..767] relationship))
        (PP (IN:[768..775] between)
          (NP
            (NP (NN:[777..781] dose))
            (CC:[782..785] and)
            (NP
              (NP (NN:[786..790] area))
              (PP (IN:[791..796] under)
                (NP (DT:[797..800] the)
                  (NML
                    (NML (NN:[801..807] plasma) (NN:[808..821] concentration))
                    (HYPH:[821..822] -) (NN:[822..826] time))
                  (NN:[827..832] curve))))))))
    (.:[832..833] .)))

;sentence 8 Span:834..1037
;Cholinesterase  inhibitors are rapidly absorbed through the gastrointestinal
;tract, with time to  peak concentration usually less than 2 hours; donepezil
;has the longest  absorption time of 3 to 5 hours.
;[834..848]:substance:"Cholinesterase"
;[850..860]:substance:"inhibitors"
;[969..970]:quantitative-value:"2"
;[971..976]:quantitative-units:"hours"
;[978..987]:substance:"donepezil"
;[1024..1030]:quantitative-value:"3 to 5"
;[1031..1036]:quantitative-units:"hours"
(SENT
  (S
    (S
      (NP-SBJ-1 (NN:[834..848] Cholinesterase) (NNS:[850..860] inhibitors))
      (VP (VBP:[861..864] are)
        (ADVP (RB:[865..872] rapidly))
        (VP (VBN:[873..881] absorbed)
          (NP-1 (-NONE-:[881..881] *))
          (PP (IN:[882..889] through)
            (NP (DT:[890..893] the) (JJ:[894..910] gastrointestinal)
                (NN:[911..916] tract)))
          (,:[916..917] ,)
          (PP (IN:[918..922] with)
            (NP
              (NP
                (NP (NN:[923..927] time))
                (PP (TO:[928..930] to)
                  (NP (JJ:[932..936] peak) (NN:[937..950] concentration))))
              (ADJP
                (ADVP (RB:[951..958] usually))
                (JJR:[959..963] less)
                (PP (IN:[964..968] than)
                  (NP (CD:[969..970] 2) (NNS:[971..976] hours)))))))))
    (::[976..977] ;)
    (S
      (NP-SBJ (NN:[978..987] donepezil))
      (VP (VBZ:[988..991] has)
        (NP
          (NP (DT:[992..995] the) (JJS:[996..1003] longest)
              (NN:[1005..1015] absorption) (NN:[1016..1020] time))
          (PP (IN:[1021..1023] of)
            (NP
              (QP (CD:[1024..1025] 3) (TO:[1026..1028] to) (CD:[1029..1030] 5))
              (NNS:[1031..1036] hours))))))
    (.:[1036..1037] .)))

;sentence 9 Span:1038..1160
;Donepezil and tacrine are highly protein bound,  whereas protein binding of
;rivastigmine and galantamine is less than 40%.
;[1038..1047]:substance:"Donepezil"
;[1052..1059]:substance:"tacrine"
;[1071..1078]:substance:"protein"
;[1095..1102]:substance:"protein"
;[1114..1126]:substance:"rivastigmine"
;[1131..1142]:substance:"galantamine"
;[1156..1159]:quantitative-value:"40%"
(SENT
  (S
    (NP-SBJ (NN:[1038..1047] Donepezil) (CC:[1048..1051] and)
            (NN:[1052..1059] tacrine))
    (VP (VBP:[1060..1063] are)
      (ADJP-PRD (RB:[1064..1070] highly) (NN:[1071..1078] protein)
                (VBN:[1079..1084] bound))
      (,:[1084..1085] ,)
      (SBAR-ADV (IN:[1087..1094] whereas)
        (S
          (NP-SBJ
            (NP (NN:[1095..1102] protein) (NN:[1103..1110] binding))
            (PP (IN:[1111..1113] of)
              (NP (NN:[1114..1126] rivastigmine) (CC:[1127..1130] and)
                  (NN:[1131..1142] galantamine))))
          (VP (VBZ:[1143..1145] is)
            (NP-PRD
              (QP (JJR:[1146..1150] less) (IN:[1151..1155] than)
                  (CD:[1156..1158] 40))
              (NN:[1158..1159] %))))))
    (.:[1159..1160] .)))

;sentence 10 Span:1162..1291
;Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil
;and  galantamine are metabolised by CYP3A4 and CYP2D6.
;[1162..1169]:substance:"Tacrine"
;[1196..1221]:cyp450:"cytochrome P450 (CYP) 1A2"
;[1227..1236]:substance:"donepezil"
;[1242..1253]:substance:"galantamine"
;[1273..1279]:cyp450:"CYP3A4"
;[1284..1290]:cyp450:"CYP2D6"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[1162..1169] Tacrine))
      (VP (VBZ:[1170..1172] is)
        (VP (VBN:[1173..1184] metabolised)
          (NP-2 (-NONE-:[1184..1184] *))
          (PP (IN:[1185..1187] by)
            (NP-LGS (JJ:[1188..1195] hepatic)
              
              (NML
                (NML (NN:[1196..1206] cytochrome) (NN:[1207..1211] P450))
                (NML (-LRB-:[1212..1213] -LRB-) (NN:[1213..1216] CYP)
                     (-RRB-:[1216..1217] -RRB-)))
              (NN:[1218..1221] 1A2))))))
    (,:[1221..1222] ,) (CC:[1223..1226] and)
    (S
      (NP-SBJ-1 (NN:[1227..1236] donepezil) (CC:[1237..1240] and)
                (NN:[1242..1253] galantamine))
      (VP (VBP:[1254..1257] are)
        (VP (VBN:[1258..1269] metabolised)
          (NP-1 (-NONE-:[1269..1269] *))
          (PP (IN:[1270..1272] by)
            (NP-LGS (NN:[1273..1279] CYP3A4) (CC:[1280..1283] and)
                    (NN:[1284..1290] CYP2D6))))))
    (.:[1290..1291] .)))

;sentence 11 Span:1292..1344
;Rivastigmine is metabolised by  sulfate conjugation.
;[1292..1304]:substance:"Rivastigmine"
(SENT
  (S
    (NP-SBJ-1 (NN:[1292..1304] Rivastigmine))
    (VP (VBZ:[1305..1307] is)
      (VP (VBN:[1308..1319] metabolised)
        (NP-1 (-NONE-:[1319..1319] *))
        (PP (IN:[1320..1322] by)
          (NP-LGS (NN:[1324..1331] sulfate) (NN:[1332..1343] conjugation)))))
    (.:[1343..1344] .)))

;sentence 12 Span:1345..1459
;Two cholinesterase enzymes are present in the body,  acetylcholinesterase
;(AChE) and butyrylcholinesterase (BChE).
;[1349..1371]:substance:"cholinesterase enzymes"
;[1398..1418]:substance:"acetylcholinesterase"
;[1420..1424]:substance:"AChE"
;[1430..1451]:substance:"butyrylcholinesterase"
;[1453..1457]:substance:"BChE"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1345..1348] Two)
         (NN:[1349..1363] cholinesterase) (NNS:[1364..1371] enzymes))
      (NP-1 (-NONE-:[1371..1371] *ICH*)))
    (VP (VBP:[1372..1375] are)
      (ADJP-PRD (JJ:[1376..1383] present)
        (PP (IN:[1384..1386] in)
          (NP (DT:[1387..1390] the) (NN:[1391..1395] body))))
      (,:[1395..1396] ,)
      (NP-1
        (NP
          (NP (NN:[1398..1418] acetylcholinesterase))
          (NP (-LRB-:[1419..1420] -LRB-) (NN:[1420..1424] AChE)
              (-RRB-:[1424..1425] -RRB-)))
        (CC:[1426..1429] and)
        (NP
          (NP (NN:[1430..1451] butyrylcholinesterase))
          (NP (-LRB-:[1452..1453] -LRB-) (NN:[1453..1457] BChE)
              (-RRB-:[1457..1458] -RRB-)))))
    (.:[1458..1459] .)))

;sentence 13 Span:1460..1569
;Tacrine and  rivastigmine inhibit both enzymes, whereas donepezil and
;galantamine  specifically inhibit AChE.
;[1460..1467]:substance:"Tacrine"
;[1473..1485]:substance:"rivastigmine"
;[1499..1506]:substance:"enzymes"
;[1516..1525]:substance:"donepezil"
;[1530..1541]:substance:"galantamine"
;[1564..1568]:substance:"AChE"
(SENT
  (S
    (NP-SBJ (NN:[1460..1467] Tacrine) (CC:[1468..1471] and)
            (NN:[1473..1485] rivastigmine))
    (VP (VBP:[1486..1493] inhibit)
      (NP (DT:[1494..1498] both) (NNS:[1499..1506] enzymes))
      (,:[1506..1507] ,)
      (SBAR-ADV (IN:[1508..1515] whereas)
        (S
          (NP-SBJ (NN:[1516..1525] donepezil) (CC:[1526..1529] and)
                  (NN:[1530..1541] galantamine))
          (ADVP (RB:[1543..1555] specifically))
          (VP (VBP:[1556..1563] inhibit)
            (NP (NN:[1564..1568] AChE))))))
    (.:[1568..1569] .)))

;sentence 14 Span:1570..1678
;Galantamine also modulates nicotine receptors,  thereby enhancing
;acetylcholinergic activity at the synapse.
;[1570..1581]:substance:"Galantamine"
;[1597..1615]:substance:"nicotine receptors"
(SENT
  (S
    (NP-SBJ (NN:[1570..1581] Galantamine))
    (ADVP (RB:[1582..1586] also))
    (VP (VBZ:[1587..1596] modulates)
      (NP (NN:[1597..1605] nicotine) (NNS:[1606..1615] receptors))
      (,:[1615..1616] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1616..1616] *))
        (ADVP (RB:[1618..1625] thereby))
        (VP (VBG:[1626..1635] enhancing)
          (NP (JJ:[1636..1653] acetylcholinergic) (NN:[1654..1662] activity))
          (PP-LOC (IN:[1663..1665] at)
            (NP (DT:[1666..1669] the) (NN:[1670..1677] synapse))))))
    (.:[1677..1678] .)))

;sentence 15 Span:1679..1763
;These different  pharmacological profiles provide distinctions between these
;agents.
;[1756..1762]:substance:"agents"
(SENT
  (S
    (NP-SBJ (DT:[1679..1684] These) (JJ:[1685..1694] different)
            (JJ:[1696..1711] pharmacological) (NNS:[1712..1720] profiles))
    (VP (VBP:[1721..1728] provide)
      (NP
        (NP (NNS:[1729..1741] distinctions))
        (PP (IN:[1742..1749] between)
          (NP (DT:[1750..1755] these) (NNS:[1756..1762] agents)))))
    (.:[1762..1763] .)))

;sentence 16 Span:1765..1896
;Cholinesterase inhibitors show a nonlinear relationship between dose and 
;cholinesterase inhibition, where a plateau effect occurs.
;[1765..1779]:substance:"Cholinesterase"
;[1780..1790]:substance:"inhibitors"
;[1839..1853]:substance:"cholinesterase"
(SENT
  (S
    (NP-SBJ (NN:[1765..1779] Cholinesterase) (NNS:[1780..1790] inhibitors))
    (VP (VBP:[1791..1795] show)
      (NP
        (NP (DT:[1796..1797] a) (JJ:[1798..1807] nonlinear)
            (NN:[1808..1820] relationship))
        (PP (IN:[1821..1828] between)
          (NP
            (NP (NN:[1829..1833] dose))
            (CC:[1834..1837] and)
            (NP (NN:[1839..1853] cholinesterase) (NN:[1854..1864] inhibition))))
        (,:[1864..1865] ,)
        (S-ADV
          (WHADVP-1 (WRB:[1866..1871] where))
          (S
            (NP-SBJ (DT:[1872..1873] a) (NN:[1874..1881] plateau)
                    (NN:[1882..1888] effect))
            (VP (VBZ:[1889..1895] occurs)
              (ADVP-1 (-NONE-:[1895..1895] *T*)))))))
    (.:[1895..1896] .)))

;sentence 17 Span:1897..2007
;Cholinesterase  inhibitors display a different profile as each agent achieves
;its plateau at  different doses.
;[1897..1911]:substance:"Cholinesterase"
;[1913..1923]:substance:"inhibitors"
;[1960..1965]:substance:"agent"
(SENT
  (S
    (NP-SBJ (NN:[1897..1911] Cholinesterase) (NNS:[1913..1923] inhibitors))
    (VP (VBP:[1924..1931] display)
      (NP (DT:[1932..1933] a) (JJ:[1934..1943] different)
          (NN:[1944..1951] profile))
      (SBAR-ADV (IN:[1952..1954] as)
        (S
          (NP-SBJ (DT:[1955..1959] each) (NN:[1960..1965] agent))
          (VP (VBZ:[1966..1974] achieves)
            (NP (PRP$:[1975..1978] its) (NN:[1979..1986] plateau))
            (PP-LOC (IN:[1987..1989] at)
              (NP (JJ:[1991..2000] different) (NNS:[2001..2006] doses)))))))
    (.:[2006..2007] .)))

;sentence 18 Span:2008..2130
;In clinical trials, cholinesterase inhibitors demonstrate a  dose-dependent
;effect on cognition and functional activities.
;[2028..2042]:substance:"cholinesterase"
;[2043..2053]:substance:"inhibitors"
(SENT
  (S
    (PP-LOC (IN:[2008..2010] In)
      (NP (JJ:[2011..2019] clinical) (NNS:[2020..2026] trials)))
    (,:[2026..2027] ,)
    (NP-SBJ (NN:[2028..2042] cholinesterase) (NNS:[2043..2053] inhibitors))
    (VP (VBP:[2054..2065] demonstrate)
      (NP (DT:[2066..2067] a)
        (ADJP (NN:[2069..2073] dose) (HYPH:[2073..2074] -)
              (JJ:[2074..2083] dependent))
        (NN:[2084..2090] effect))
      (PP (IN:[2091..2093] on)
        (NP
          (NP (NN:[2094..2103] cognition))
          (CC:[2104..2107] and)
          (NP (JJ:[2108..2118] functional) (NNS:[2119..2129] activities)))))
    (.:[2129..2130] .)))

;sentence 19 Span:2131..2222
;Improvement in  behavioural symptoms also occurs, but without a dose-response
;relationship.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2131..2142] Improvement))
      (PP (IN:[2143..2145] in)
        (NP (JJ:[2147..2158] behavioural) (NNS:[2159..2167] symptoms))))
    (VP
      (VP=1
        (ADVP (RB:[2168..2172] also))
        (VBZ:[2173..2179] occurs))
      (,:[2179..2180] ,) (CC:[2181..2184] but)
      (VP=1
        (PP-MNR (IN:[2185..2192] without)
          (NP (DT:[2193..2194] a)
            (NML (NN:[2195..2199] dose) (HYPH:[2199..2200] -)
                 (NN:[2200..2208] response))
            (NN:[2209..2221] relationship)))))
    (.:[2221..2222] .)))

;sentence 20 Span:2224..2273
;Gastrointestinal adverse events are dose-related.
(SENT
  (S
    (NP-SBJ (JJ:[2224..2240] Gastrointestinal) (JJ:[2241..2248] adverse)
            (NNS:[2249..2255] events))
    (VP (VBP:[2256..2259] are)
      (ADJP-PRD (NN:[2260..2264] dose) (HYPH:[2264..2265] -)
                (VBN:[2265..2272] related)))
    (.:[2272..2273] .)))

;sentence 21 Span:2274..2356
;Clinical improvement occurs  with between 40 and 70% inhibition of
;cholinesterase.
;[2316..2318]...[2325..2326]:quantitative-value:"40"..."%"
;[2323..2326]:quantitative-value:"70%"
;[2341..2355]:substance:"cholinesterase"
(SENT
  (S
    (NP-SBJ (JJ:[2274..2282] Clinical) (NN:[2283..2294] improvement))
    (VP (VBZ:[2295..2301] occurs)
      (PP (IN:[2303..2307] with)
        (PP (IN:[2308..2315] between)
          (NP
            (NP
              (NP
                (NML (CD:[2316..2318] 40)
                  (NML-1 (-NONE-:[2318..2318] *P*)))
                (NML-2 (-NONE-:[2318..2318] *P*)))
              (CC:[2319..2322] and)
              (NP
                (NML (CD:[2323..2325] 70)
                  (NML-1 (NN:[2325..2326] %)))
                (NML-2 (NN:[2327..2337] inhibition))))
            (PP (IN:[2338..2340] of)
              (NP (NN:[2341..2355] cholinesterase)))))))
    (.:[2355..2356] .)))

;sentence 22 Span:2357..2492
;A conceptual model for  cholinesterase inhibitors has been proposed, linking
;enzyme inhibition, clinical  efficacy and adverse effects.
;[2381..2395]:substance:"cholinesterase"
;[2396..2406]:substance:"inhibitors"
;[2434..2440]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2357..2358] A) (JJ:[2359..2369] conceptual)
          (NN:[2370..2375] model))
      (PP (IN:[2376..2379] for)
        (NP (NN:[2381..2395] cholinesterase) (NNS:[2396..2406] inhibitors))))
    (VP (VBZ:[2407..2410] has)
      (VP (VBN:[2411..2415] been)
        (VP (VBN:[2416..2424] proposed)
          (NP-1 (-NONE-:[2424..2424] *))
          (,:[2424..2425] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[2425..2425] *))
            (VP (VBG:[2426..2433] linking)
              (NP
                (NP (NN:[2434..2440] enzyme) (NN:[2441..2451] inhibition))
                (,:[2451..2452] ,)
                (NP (JJ:[2453..2461] clinical) (NN:[2463..2471] efficacy))
                (CC:[2472..2475] and)
                (NP (JJ:[2476..2483] adverse) (NNS:[2484..2491] effects))))))))
    (.:[2491..2492] .)))

;sentence 23 Span:2493..2593
;Currently, measurement of enzyme inhibition is  used as the biomarker for
;cholinesterase inhibitors.
;[2519..2525]:substance:"enzyme"
;[2567..2581]:substance:"cholinesterase"
;[2582..2592]:substance:"inhibitors"
(SENT
  (S
    (ADVP-TMP (RB:[2493..2502] Currently))
    (,:[2502..2503] ,)
    (NP-SBJ-1
      (NP (NN:[2504..2515] measurement))
      (PP (IN:[2516..2518] of)
        (NP (NN:[2519..2525] enzyme) (NN:[2526..2536] inhibition))))
    (VP (VBZ:[2537..2539] is)
      (VP (VBN:[2541..2545] used)
        (NP-1 (-NONE-:[2545..2545] *))
        (PP (IN:[2546..2548] as)
          (NP
            (NP (DT:[2549..2552] the) (NN:[2553..2562] biomarker))
            (PP (IN:[2563..2566] for)
              (NP (NN:[2567..2581] cholinesterase) (NNS:[2582..2592] inhibitors)))))))
    (.:[2592..2593] .)))

;sentence 24 Span:2594..2733
;New approaches to  determining the efficacy of cholinesterase inhibitors in
;the brain could involve  the use of various imaging techniques.
;[2641..2655]:substance:"cholinesterase"
;[2656..2666]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[2594..2597] New) (NNS:[2598..2608] approaches))
      (PP (TO:[2609..2611] to)
        (S-NOM
          (NP-SBJ (-NONE-:[2611..2611] *))
          (VP (VBG:[2613..2624] determining)
            (NP
              (NP (DT:[2625..2628] the) (NN:[2629..2637] efficacy))
              (PP (IN:[2638..2640] of)
                (NP (NN:[2641..2655] cholinesterase)
                    (NNS:[2656..2666] inhibitors))))
            (PP-LOC (IN:[2667..2669] in)
              (NP (DT:[2670..2673] the) (NN:[2674..2679] brain)))))))
    (VP (MD:[2680..2685] could)
      (VP (VB:[2686..2693] involve)
        (NP
          (NP (DT:[2695..2698] the) (NN:[2699..2702] use))
          (PP (IN:[2703..2705] of)
            (NP (JJ:[2706..2713] various) (VBG:[2714..2721] imaging)
                (NNS:[2722..2732] techniques))))))
    (.:[2732..2733] .)))

;sentence 25 Span:2734..2850
;The knowledge base for the  pharmacokinetics and pharmacodynamics of
;cholinesterase inhibitors continues to  expand.
;[2803..2817]:substance:"cholinesterase"
;[2818..2828]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2734..2737] The) (NN:[2738..2747] knowledge)
          (NN:[2748..2752] base))
      (PP (IN:[2753..2756] for)
        (NP
          (NP (DT:[2757..2760] the) (NNS:[2762..2778] pharmacokinetics)
              (CC:[2779..2782] and) (NNS:[2783..2799] pharmacodynamics))
          (PP (IN:[2800..2802] of)
            (NP (NN:[2803..2817] cholinesterase) (NNS:[2818..2828] inhibitors))))))
    (VP (VBZ:[2829..2838] continues)
      (S
        (NP-SBJ (-NONE-:[2838..2838] *))
        (VP (TO:[2839..2841] to)
          (VP (VB:[2843..2849] expand)))))
    (.:[2849..2850] .)))

;sentence 26 Span:2851..2994
;The increased information available to clinicians can optimise the use  of
;these agents in the management of patients with Alzheimer's disease.
;[2932..2938]:substance:"agents"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2851..2854] The) (VBN:[2855..2864] increased)
          (NN:[2865..2876] information))
      (ADJP (JJ:[2877..2886] available)
        (PP (TO:[2887..2889] to)
          (NP (NNS:[2890..2900] clinicians)))))
    (VP (MD:[2901..2904] can)
      (VP (VB:[2905..2913] optimise)
        (NP
          (NP (DT:[2914..2917] the) (NN:[2918..2921] use))
          (PP (IN:[2923..2925] of)
            (NP (DT:[2926..2931] these) (NNS:[2932..2938] agents))))
        (PP (IN:[2939..2941] in)
          (NP
            (NP (DT:[2942..2945] the) (NN:[2946..2956] management))
            (PP (IN:[2957..2959] of)
              (NP
                (NP (NNS:[2960..2968] patients))
                (PP (IN:[2969..2973] with)
                  (NP
                    (NP (NNP:[2974..2983] Alzheimer) (POS:[2983..2985] 's))
                    (NN:[2986..2993] disease)))))))))
    (.:[2993..2994] .)))

;section 27 Span:2998..3016
;Publication Types:
(SEC
  (NP (NNP:[2998..3009] Publication) (NNP:[3010..3015] Types) (::[3015..3016] :)))

;section 28 Span:3022..3028
;Review
(SEC
  (NP (NNP:[3022..3028] Review)))

;section 29 Span:3034..3050
;Review, Academic
(SEC
  (NP (NNP:[3034..3040] Review) (,:[3040..3041] ,) (NNP:[3042..3050] Academic)))

;section 30 Span:3054..3099
;PMID: 12162759 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3054..3058] PMID) (::[3058..3059] :) (CD:[3060..3068] 12162759)
        (NN:[3069..3070] -LSB-) (NNP:[3070..3076] PubMed) (::[3077..3078] -)
        (NN:[3079..3086] indexed) (IN:[3087..3090] for)
        (NNP:[3091..3099] MEDLINE-RSB-)))